EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
8.35
-0.61 (-6.76%)
Nov 21, 2024, 4:00 PM EST - Market closed
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for EYPT stock have an average target of 27.29, with a low estimate of 15 and a high estimate of 44. The average target predicts an increase of 226.83% from the current stock price of 8.35.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for EYPT stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $22 | Strong Buy | Maintains | $30 → $22 | +163.47% | Nov 11, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $33 | Strong Buy | Maintains | $28 → $33 | +295.21% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 | Strong Buy | Maintains | $28 | +235.33% | Oct 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +259.28% | Oct 25, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $18 | Buy | Initiates | $18 | +115.57% | Oct 16, 2024 |
Financial Forecast
Revenue This Year
44.63M
from 46.02M
Decreased by -3.01%
Revenue Next Year
14.82M
from 44.63M
Decreased by -66.81%
EPS This Year
-2.36
from -1.82
EPS Next Year
-3.18
from -2.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 59.9M | 25.0M | 48.9M | ||
| Avg | 44.6M | 14.8M | 8.9M | ||
| Low | 31.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 30.1% | -43.9% | 230.3% | ||
| Avg | -3.0% | -66.8% | -40.0% | ||
| Low | -32.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.19 | -2.48 | -2.14 | ||
| Avg | -2.36 | -3.18 | -3.46 | ||
| Low | -2.53 | -4.03 | -4.71 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.